Equine Aβ42 antibody and antigen (recombinant protein)

Diagnostic anti-Equine Aβ42 antibodies pairs and antigen for animal health (animal Equine/Horse Alzheimer Disease(AD)) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Equine disease testing products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-EQU-AB42-Ag01Equine Aβ42$3090.00
GMP-EQU-AB42-Ab01Anti-Equine Aβ42 mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-AB42-Ab02Anti-Equine Aβ42 mouse monoclonal antibody (mAb)$3090.00
GMP-EQU-AB42-Ab03Anti-Equine Aβ42 human monoclonal antibody (mAb)$3090.00
GMP-EQU-AB42-Ab04Anti-Equine Aβ42 human monoclonal antibody (mAb)$3090.00

Size： 1mg | 10mg | 100mg



Product Description

Cat No. GMP-EQU-AB42-Ag01
Product NameEquine Aβ42
Target/BiomarkerEquine Aβ42
Expression platformE.coli
IsotypesRecombinant Antigen
Bioactivity validationAnti-Equine Aβ42 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ42 level test of animal Equine/Horse with Alzheimer Disease(AD).
TagHis
Reconized/Reactive SpecicsEquine Aβ42
Product descriptionRecombinant Equine Aβ42 protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-AB42-Ab01,GMP-EQU-AB42-Ab02
Target/BiomarkerEquine Aβ42
Product NameAnti-Equine Aβ42 mouse monoclonal antibody (mAb)
Expression platformCHO
Isotypes Mouse IgG
Bioactivity validationRecombinant Equine Aβ42 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine Aβ42 antibodies in Equine Aβ42 level test of animal Equine/Horse with Alzheimer Disease(AD).
Product descriptionAnti-Equine Aβ42 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine Aβ42 antibodies.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No.GMP-EQU-AB42-Ab03,GMP-EQU-AB42-Ab04
Target/BiomarkerEquine Aβ42
Product NameAnti-Equine Aβ42 human monoclonal antibody (mAb)
Expression platformCHO
IsotypesHuman lgG1
Bioactivity validationRecombinant Equine Aβ42 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine Aβ42 antibodies in Equine Aβ42 level test of animal Equine/Horse with Alzheimer Disease(AD).
Product descriptionAnti-Equine Aβ42 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
PurityPurity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Validation Data


    Click to get more Data / Case study about the product.



    Target/Biomarker Information


    Equine Amyloid-beta 42 (Aβ42) emerges as a pivotal molecule in equine neuroscience, occupying a central role in our understanding of neurodegenerative conditions affecting our noble equine companions. Comprising 42 amino acids, Aβ42 is a fragment of the amyloid precursor protein (APP) and stands as a critical component in the formation of amyloid plaques within the equine brain. These plaques, primarily composed of Aβ42, have come to symbolize cognitive decline in horses, most notably in cases of equine cognitive dysfunction syndrome (ECDS).

    The genesis of Aβ42 involves the proteolytic cleavage of APP, a process mediated by β-secretase and γ-secretase enzymes. In horses afflicted by ECDS, a perturbation in Aβ42 metabolism and clearance results in its aggregation, leading to the accumulation of amyloid plaques. These plaques pose a direct threat to normal neuronal function, contributing substantially to the cognitive and memory impairments observed in affected horses.

    The ramifications of Aβ42 aggregation extend further, encompassing a cascade of deleterious effects. These include neuroinflammation, oxidative stress, and synaptic dysfunction, all of which collectively contribute to the progressive cognitive deficits witnessed in horses suffering from ECDS.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.